mobihealthnews featured the study that demonstrated people with both diabetes and uncontrolled high blood pressure who used the Livongo for Hypertension solution saw significant declines in their blood pressure within six weeks.
March 18, 2019 by: Jonah Comstock
At the American College of Cardiology this past weekend, chronic disease management platform Livongo reported on six-month results from its first major study of its hypertension management platform, which is already in use with many of its customers.
The study looked at 708 individuals with both diabetes and hypertension. Patients whose blood pressure was higher than 130/80 mm Hg saw their systolic blood pressure drop by an average of 11.2 mm Hg and their diastolic pressure drop by an average of 5.2 mm Hg after six weeks in the program, which included digital coaching and self-monitoring with a smartphone-connected blood pressure cuff.
Research also showed that people were engaging with the program and keeping up with their self-monitoring.
mobihealthnews’ full article about Livongo’s study here.